• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    President and CEO Altman Peter bought $214 worth of shares (100 units at $2.14), increasing direct ownership by 0.09% to 112,720 units (SEC Form 4)

    4/17/25 7:44:23 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCDA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Altman Peter

    (Last) (First) (Middle)
    C/O BIOCARDIA, INC.
    320 SOQUEL WAY

    (Street)
    SUNNYVALE CA 94085

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BioCardia, Inc. [ BCDA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    04/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/15/2025 P 100 A $2.14 112,720 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ David McClung, by power of attorney 04/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCDA

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Krasno Richard M bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 417% to 16,268 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/28/25 6:46:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mcclung David bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 44% to 43,131 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:38:27 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Facteau Bill bought $24,999 worth of shares (13,123 units at $1.90) (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:37:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    SEC Filings

    See more
    • BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BioCardia, Inc. (0000925741) (Filer)

      5/6/25 8:00:09 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioCardia, Inc. (0000925741) (Filer)

      5/1/25 9:00:10 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by BioCardia Inc.

      S-3 - BioCardia, Inc. (0000925741) (Filer)

      4/30/25 5:13:07 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $BCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on BioCardia with a new price target

      HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00

      12/20/21 6:05:04 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia downgraded by Dawson James

      Dawson James downgraded BioCardia from Buy to Neutral

      4/16/21 7:22:02 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Krasno Richard M bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 417% to 16,268 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/28/25 6:46:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mcclung David bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 44% to 43,131 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:38:27 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Facteau Bill bought $24,999 worth of shares (13,123 units at $1.90) (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:37:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study

      CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of Wisconsin School of Medicine and Public Health, to serve as Site Principal Investigator and Co-National Principal Investigator SUNNYVALE, Calif., May 06, 2025 (GLOBE NEWSWIRE) --  BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that University of Wisconsin in Madison, Wisconsin is now enrolling patients with ischemic HFrEF in

      5/6/25 8:00:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure

      SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled in the Phase III randomized procedure placebo-controlled double-blind CardiAMP HF II clinical trial of the Company's lead autologous cell therapy program for the treatment of heart failure at BayCare Morton Plant Hospital in Clearwater, Florida. "We are excited to lead enrollment in the CardiAMP HF II trial and be able to offer this cell therapy study to our heart failure patients. This investigational therapy has been shown to enhance micro

      5/1/25 9:00:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioCardia Inc.

      SC 13G - BioCardia, Inc. (0000925741) (Subject)

      9/6/24 7:45:48 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      4/5/24 4:13:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      2/27/24 4:53:40 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Financials

    Live finance-specific insights

    See more
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

      SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. To access the call today:Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration. For those who have no

      3/31/25 1:39:56 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

      Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significanceStatistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with CardiAMP Cell TherapyPatient improvements through two years suggest single dose of CardiAMP therapy offers durable benefits SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for

      3/31/25 8:00:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care